How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levofloxacin-ceftriaxone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Levofloxacin + Ceftriaxone — Competitive Intelligence Brief

Levofloxacin + Ceftriaxone (Levofloxacin + Ceftriaxone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone + Third-generation cephalosporin combination. Area: Infectious Disease.

phase 3 Fluoroquinolone + Third-generation cephalosporin combination Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Levofloxacin + Ceftriaxone (Levofloxacin + Ceftriaxone) — Bayer. This combination uses a fluoroquinolone antibiotic to inhibit bacterial DNA gyrase and topoisomerase IV, while a third-generation cephalosporin inhibits bacterial cell wall synthesis, providing broad-spectrum coverage against gram-positive and gram-negative bacteria.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levofloxacin + Ceftriaxone TARGET	Levofloxacin + Ceftriaxone	Bayer	phase 3	Fluoroquinolone + Third-generation cephalosporin combination	Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins
Levofloxacin-Amox/clav.	Levofloxacin-Amox/clav.	Buddhist Tzu Chi General Hospital	marketed	Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination	Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone + Third-generation cephalosporin combination class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levofloxacin + Ceftriaxone — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin-ceftriaxone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab